{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047304","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.400354+00:00","generated_at":"2026-05-21T23:27:36.226325+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunome Q1 net loss $41.6M; cash $317.3M; varegacestat data expected H2 2025","bullets":["Net loss of $41.6M for Q1 2025; R&D expense $36.9M, G&A $10.7M.","Cash, equivalents and marketable securities $317.3M as of March 31, 2025; expected to fund operations into 2027.","Phase 3 RINGSIDE trial of varegacestat fully enrolled; topline data expected in second half of 2025.","Phase 1 for IM-1021 (ROR1 ADC) ongoing; IM-3050 (FAP radiotherapy) IND cleared, trial to start H2 2025.","Amended 2024 Inducement Plan to increase reserved shares from 2M to 3.5M for new-hire equity grants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047304","json":"https://secwatch.observer/filing/0001104659-25-047304.json","markdown":"https://secwatch.observer/filing/0001104659-25-047304.md","text":"https://secwatch.observer/filing/0001104659-25-047304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/0001104659-25-047304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/tm2514592d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:27:36.226325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}